Ustekinumab efficacy and safety in mucocutaneous multi-refractory Behçet's disease

Clin Exp Rheumatol. 2017 Nov-Dec;35 Suppl 108(6):130-131. Epub 2017 Sep 7.

Authors

Giuseppe Lopalco¹, Claudia Fabiani², Vincenzo Venerito¹, Giovanni Lapadula¹, Florenzo Iannone¹, Luca Cantarini³

Affiliations

¹ Department of Emergency and Organ Transplantation, Rheumatology Unit, University of Bari, Italy.
² Department of Ophthalmology, Humanitas Research Centre, Milan, Italy.
³ Research Centre of Systemic Autoinflammatory Diseases and Behçet's Disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Italy. [email protected].

PMID: 28980903

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adult
Anti-Inflammatory Agents / therapeutic use*
Behcet Syndrome / diagnosis
Behcet Syndrome / drug therapy*
Behcet Syndrome / immunology
Drug Resistance
Drug Substitution
Female
Humans
Oral Ulcer / diagnosis
Oral Ulcer / drug therapy*
Oral Ulcer / immunology
Remission Induction
Skin / drug effects*
Skin / immunology
Skin / pathology
Treatment Outcome
Ustekinumab / therapeutic use*

Substances

Anti-Inflammatory Agents
Ustekinumab